Graft-versus-Host Disease (GvHD)
What is Graft-versus-Host Disease (GvHD)?
Graft-versus-Host Disease, or GvHD, happens after a bone marrow or stem cell transplant. The donated immune cells recognize your body as foreign. They begin attacking your healthy tissues instead of protecting you.
This condition only occurs in people who receive donated bone marrow or stem cells from another person. The donor cells are called the graft. Your body is the host. When the graft attacks the host, you develop GvHD.
GvHD can be acute or chronic. Acute GvHD typically appears within the first 100 days after transplant. Chronic GvHD develops later, sometimes months or years after your procedure. Both types can affect multiple organs including your skin, liver, digestive system, and lungs.
Symptoms
- Red, itchy rash that may blister or peel
- Yellowing of skin or eyes, known as jaundice
- Nausea, vomiting, or stomach cramping
- Diarrhea, sometimes bloody or severe
- Loss of appetite and unexplained weight loss
- Dry, burning eyes or vision changes
- Dry mouth and mouth sores
- Shortness of breath or persistent cough
- Joint stiffness or muscle weakness
- Fever or signs of infection
Some patients experience mild symptoms that appear gradually. Others develop severe symptoms that require immediate medical attention. The severity and combination of symptoms vary widely from person to person.
Concerned about Graft-versus-Host Disease (GvHD)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
GvHD occurs when donor immune cells identify your body tissues as threats. Your donor's T cells, a type of white blood cell, drive this attack. Even when donors are carefully matched to recipients, small genetic differences can trigger this response. The closer the genetic match between donor and recipient, the lower the risk of developing GvHD.
Several factors increase your risk of GvHD. Using an unrelated donor raises your risk compared to using a sibling donor. Older donor age and older recipient age both increase risk. The type of transplant matters too. Peripheral blood stem cell transplants carry higher risk than bone marrow transplants. Finally, mismatches in tissue types between donor and recipient significantly raise your chances of developing this condition.
How it's diagnosed
Doctors diagnose GvHD based on your symptoms, physical exam, and medical history. Your transplant team watches you closely for early warning signs. Blood tests help monitor liver function and look for inflammation markers. Specialized genetic tests can identify whether donor cells or your original cells remain in your body after transplant.
Your doctor may perform a biopsy of affected tissue to confirm the diagnosis. Skin biopsies are common for rash symptoms. Endoscopy with intestinal biopsies helps diagnose digestive tract involvement. Liver biopsies may be needed if blood tests show abnormal liver function. Talk to your transplant specialist about which monitoring tests are right for your situation. These specialized tests go beyond routine blood work.
Treatment options
- Immunosuppressive medications like steroids to calm the immune response
- Targeted drugs such as ruxolitinib or ibrutinib for resistant cases
- Topical treatments for skin symptoms including steroid creams
- Protective skin care to prevent infection and moisture loss
- Nutritional support and dietary changes for digestive symptoms
- Eye drops and oral rinses for dryness and discomfort
- Physical therapy to maintain mobility and strength
- Infection prevention measures including vaccines when safe
- Regular monitoring by your transplant team
- Prompt treatment of any new symptoms or complications
Frequently asked questions
Acute GvHD typically develops within 100 days of your transplant and often affects skin, liver, and digestive tract. Chronic GvHD appears later, sometimes months or years after transplant, and can affect multiple organs with symptoms similar to autoimmune diseases. Some patients develop chronic GvHD without ever having the acute form. Both types require ongoing medical management.
Doctors take several steps to reduce GvHD risk, though they cannot eliminate it entirely. Medications that suppress your immune system start before your transplant and continue afterward. Careful donor selection with close genetic matching helps reduce risk. Some transplant centers remove certain T cells from donor grafts before transplanting them. Despite these measures, many transplant recipients still develop some degree of GvHD.
GvHD severity ranges from mild to life-threatening depending on which organs are affected and how severe the symptoms become. Mild cases may cause minor skin changes that resolve with treatment. Severe cases can damage multiple organs and lead to serious complications including infection, malnutrition, and organ failure. Your transplant team monitors you closely and adjusts treatment based on your response.
The earliest signs often include a red, itchy rash on your palms, soles, ears, or face. You might notice yellowing of your skin or eyes. Digestive symptoms like nausea, cramping, or diarrhea are also common early warning signs. Report any new symptoms to your transplant team immediately. Early detection and treatment lead to better outcomes.
Yes, regular blood tests help your doctors monitor your condition and treatment response. Liver function tests detect early organ involvement. Complete blood counts check for complications from medications. Specialized genetic tests can show whether donor or recipient cells predominate in your body. Your transplant team determines which tests you need and how often based on your individual situation.
Mild acute GvHD sometimes resolves with minimal treatment, but most cases require medication to control the immune response. Chronic GvHD rarely goes away completely without treatment. Some patients achieve remission where symptoms disappear, but the condition can flare up again. Most people need ongoing treatment and monitoring for extended periods, sometimes years after their transplant.
No, GvHD does not mean transplant failure. In fact, mild GvHD can be a positive sign that donor immune cells are active in your body. These same cells that cause GvHD also attack any remaining cancer cells, creating a beneficial effect doctors call graft-versus-tumor response. Your transplant team aims to balance managing GvHD while preserving this protective effect against cancer recurrence.
Protect your skin from sun exposure, as GvHD and medications make you more sensitive to UV damage. Eat small, frequent meals if you have digestive symptoms, and avoid spicy or acidic foods. Practice good mouth hygiene to prevent infections. Stay hydrated and maintain gentle physical activity as tolerated. Avoid sick contacts and practice careful hand washing since immunosuppressive drugs increase infection risk.
Treatment duration varies widely based on disease severity and your response to therapy. Some patients need only a few months of treatment. Others require medications for years to keep symptoms controlled. Your doctors gradually taper medications when possible to find the lowest dose that manages your symptoms. Never stop or change medications without consulting your transplant team.
Many people continue normal activities during GvHD treatment, though you may need accommodations based on your symptoms and energy level. Fatigue is common with both the condition and treatments. Your immunosuppressed state means avoiding crowded places during cold and flu season. Talk with your transplant team about what activities are safe for you. Return to work or school gradually as your condition stabilizes.